Table of contents

EHDN Plenary Meeting: abstracts

• Pathogenic mechanisms: A01 Molecular mechanisms underlying polyglutamine length influence on huntingtin interactions (16 November, 2010)

  A Davranche, F Klein, D Altschuh, G Zeder-Lutz, C Weber, Y Trottier
• Pathogenic mechanisms: A02 Visualisation of mutant huntingtin oligomerisation in living cells (16 November, 2010)

  F Herrera, S Tenreiro, T Fleming Outeiro
• Pathogenic mechanisms: A03 Protein localisation studies: where is huntingtin hiding? (16 November, 2010)

  A Hughes, N Ersoy, L Elliston, L Jones
• Pathogenic mechanisms: A04 Caspase 6 resistant mutant huntingtin does not rescue the toxic effects of caspase cleavable mutant huntingtin in vivo (16 November, 2010)

  R K Graham, Y Deng, M A Pouladi, K Vaid, Y Xie, N Bissada, S Franciosi, M R Hayden
• Pathogenic mechanisms: A05 Cellular and regional gene expression changes in human Huntington's disease cortex correlate with symptom profiles (16 November, 2010)

  D Thu, D Oorschot, L Tippett, V Hogg, H Waldvogel, R Faull, R Luthi-Carter
• Pathogenic mechanisms: A06 Effects of mutant huntingtin on cortical neuron connectivity and activity dependent gene expression (16 November, 2010)

  T Seredenina, L Gambazzi, O Gokce, E Katsyuba, H Runne, H Markram, M Giugliano, R Luthi-Carter
• Pathogenic mechanisms: A07 Transcriptional activation of Neuron Restrictive Silencer Factor by sp1 in Huntington's disease (16 November, 2010)

  Y Trottier, M Ravache, C Weber, K Mérienne
• Pathogenic mechanisms: A08 Metallothioneins and copper metabolism: candidate therapeutic targets in Huntington's disease (16 November, 2010)

  A Wyttenbach, S Hands, R Mason, M U Sajjad, F Giorgini
• Pathogenic mechanisms: A09 Characterisation of AMPK activity in models of Huntington's disease pathogenesis (16 November, 2010)

  R Vazquez-Manrique, K Cambon, N Offner, A Darbois, A-M Orfila, N Déglon, C Néri
• Pathogenic mechanisms: A10 SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis (16 November, 2010)

  D Taylor, J Pallos, E Lambert, A Amore, A Parker, H Moffitt, D Smith, H Runne, O Gokce, A Kuhn, Z Xiang, M Maxwell, S Reeves, G Bates, C Néri, L Thompson, L Marsh, A Kazantsev, R Luthi-Carter
• Pathogenic mechanisms: A11 Alterations in the PGC-1 α dependent oxidative stress response in the R6/2 mouse model of HD (16 November, 2010)

  H C Sandtner, C Fleischer, T Lenk, G B Landwehrmeyer, K S Lindenberg
• Pathogenic mechanisms: A12 Mitochondrial proteome analysis of R6/2 mouse brains (16 November, 2010)

  C Fleischer, S Lehnert, O Jahn, M Otto, G B Landwehrmeyer, K S Lindenberg
• Pathogenic mechanisms: A13 Mutant huntingtin induces activation of Bcl-2/adenovirus E1B 19-kDa interacting protein (BNIP3) (16 November, 2010)

  J Sassone, C Colciago, M Figini, P Marchi, F Colleoni, A Di Pardo, R Zippel, Y Torrente, S Sipione, V Silani, A Ciammola
• Pathogenic mechanisms: A14 Fast axonal transport of mitochondria is altered in Huntington's disease (16 November, 2010)

  L E Clemens, A Grierson, K De Vos, O Riess, H P Nguyen
• Pathogenic mechanisms: A15 Genotype and ageing dependent mitochondrial abnormalities and increased caspase activities in Huntington's disease lymphoblasts (16 November, 2010)

  V Maglione, E Amico, F Squitieri
• Pathogenic mechanisms: A16 Endoplasmic reticulum stress: an initiator of neuroinflammation in Huntington's disease? (16 November, 2010)

  K R Ayasolla, R K Kalathur, M E Futschik
• Pathogenic mechanisms: A17 Myeloid cell function in mouse models of Huntington's disease (16 November, 2010)

  R André, U Schure, A Magnusson, N Lahiri, D Smith, M W Lowdell, G Bates, M Bjorkqvist, S J Tabrizi
• Pathogenic mechanisms: A18 Cellular signalling of human monocytes in Huntington's disease (16 November, 2010)

  U Schure, A Magnusson, N Lahiri, R André, S Rabbanian, M W Lowdell, M Bjorkqvist, S J Tabrizi
• Pathogenic mechanisms: A19 Early defect of transforming growth factor β1 formation in Huntington's disease (16 November, 2010)

  F Squitieri, G Battaglia, M Cannella, B Riozzi, S Orobello, M L Maat-Schieman, E Aronica, C L Busceti, A Ciarmiello, S Alberti, J Sassone, S Sipione, V Bruno, L Frati, F Nicoletti
• Pathogenic mechanisms: A20 Interaction of huntingtin and the ryanodine receptor (16 November, 2010)

  K S Lindenberg, A Davranche, F Klein, A V Thomas, C Lill, T Lenk, L R Orlando, J Kama, A B Young, G B Landwehrmeyer, Y Trottier
• Pathogenic mechanisms: A21 Altered calcium kinetics in skeletal muscle fibres of the R6/2 mouse model of HD (16 November, 2010)

  P Braubach, Z Andronache, A Riecker, K S Lindenberg, G B Landwehrmeyer, F Lehmann-Horn, W Melzer
• Pathogenic mechanisms: A22 Hypothalamic changes in Huntington's disease (16 November, 2010)

  D van Wamelen, A Aziz, L Shan, J Anink, R A C Roos, D Swaab
• Pathogenic mechanisms: A23 Changes in key hypothalamic neuropeptide populations in Huntington's Disease revealed by neuropathological analyses (16 November, 2010)

  S Gabery, K Murphy, K Schultz, C Loy, E McCusker, D Kirik, G Halliday, Å Petersén
• Pathogenic mechanisms: A24 Hypothalamic expression of mutant huntingtin causes metabolic disturbances in mice (16 November, 2010)

  R Soylu, S Hult, T Björklund, B F Belgardt, J Mauer, J C Brüning, D Kirik, Å Petersén
• Pathogenic mechanisms: A25 Psychiatric and metabolic changes in the BACHD mouse model of Huntington's disease (16 November, 2010)

  S Hult, R Soylu, D Kirik, Å Petersén
• Pathogenic mechanisms: A26 Transgenic miniature pig as an animal model for Huntington's disease (16 November, 2010)

  M Baxa, S Juhas, A Pavlok, P Vodicka, J Juhasova, M Hruška-Plocháň, A Miyanohara, M Marsala, E Cattaneo, M Difiglia, J Motlik
• Pathogenic mechanisms: A27 Expression of the human mutant huntingtin in minipig striatum induced formation of EM48+ inclusions in the neuronal nuclei, cytoplasm and processes (16 November, 2010)

  M Hruška-Plocháň, S Juhas, J Juhasova, J Galik, A Miyanohara, M Marsala, C R Bjarkam, E Cattaneo, M DiFiglia, X-J Li, J Motlik
• Pathogenic mechanisms: A28 Accumulation and aggregation of human mutant huntingtin and neuron atrophy in BAC-HD transgenic rat (16 November, 2010)

  L Yu, S Metzger, L E Clemens, J Ehrismann, T Ott, X Gu, M Gray, W Yang, A P Osmand, O Riess, H P Nguyen
• Pathogenic mechanisms: A29 Frontostriatal pathology in the (C57BL/6J) YAC128 mouse uncovered by the operant delayed alternation task (16 November, 2010)

  S Brooks, L Jones, S B Dunnett
• Pathogenic mechanisms: A30 Identification of MOAG-4/SERF as a regulator of age related proteotoxicity (16 November, 2010)

  R Burggraaff, T van Ham, M Holmberg, A van der Goot, E Teuling, M Garcia-Arencibia, H-E Kim, D Du, K Thijssen, M Wiersma, P van Bergeijk, J van Rheenen, J van Veluw, R Hofstra, D C Rubinsztein, E Nollen
• Pathogenic mechanisms: A31 Network based analyses of Huntington's disease (16 November, 2010)

  R K Kalathur, M E Futschik
• Pathogenic mechanisms: A32 A systems biology approach towards deciphering the unfolded protein response in Huntington's disease (16 November, 2010)

  K R Ayasolla, R K Kalathur, M E Futschik
• Pathogenic mechanisms: A33 Behavioural evaluation of Huntington's disease mouse models with an automated home cage system (16 November, 2010)

  J Magg, E Portal, A Kelp, J Ehrismann, G Pahnke, O Riess, H P Nguyen
• Experimental therapeutics: preclinical: B01 Identification and validation of candidate therapeutic targets for Huntington's disease (16 November, 2010)

  J Clapp, F Giorgini
• Experimental therapeutics: preclinical: B02 Validation of suppressors of mutant huntingtin toxicity in a fly model of Huntington's disease (16 November, 2010)

  M Casu, S Campesan, J Clapp, C P Kyriacou, F Giorgini
• Experimental therapeutics: preclinical: B03 Identification and characterisation of overexpression suppressors of mutant huntingtin toxicity (16 November, 2010)

  R Mason, N Fearnley, C Bishop, T Möller, F Giorgini
• Experimental therapeutics: preclinical: B04 A genetic screen targeting suppressors of aggregation and neurodegeneration in a Drosophila Huntington's disease model (16 November, 2010)

  K Weiss, Y Kimura, W-C M Lee, T Littleton
• Experimental therapeutics: preclinical: B05 Towards the unbiased prioritisation of Huntington's Disease targets using network based analysis of genome wide datasets (16 November, 2010)

  L Mesrob, F-X Lejeune, C Bicep, J-PC Vert, C Néri, the Core Working Group Biological modifiers of the European Huntington's Disease Network
• Experimental therapeutics: preclinical: B06 Validation of KMO as a candidate therapeutic target for Huntington's disease in Drosophila melanogaster (16 November, 2010)

  S Campesan, E W Green, K V Sathyasaikumar, C Breda, P J Muchowski, R Schwarcz, C P Kyriacou, F Giorgini
• Experimental therapeutics: preclinical: B07 Identification of protein interaction partners for kynurenine 3-monooxygenase, a candidate therapeutic target for Huntington's disease (16 November, 2010)

  M Thevandavakkam, L M Fleming, R Mason, T Fleming Outeiro, F Giorgini
• Experimental therapeutics: preclinical: B08 Reduction of prolonged cag repeat containing alleles in Huntington's disease using antisense oligonucleotides (16 November, 2010)

  M M Evers, J C T van Deutekom, S A M Mulders, A M Aartsma-Rus, A Weiss, A Roscic, J T den Dunnen, G-J B van Ommen, W M C van Roon-Mom
• Experimental therapeutics: preclinical: B09 One antisense oligonucleotide as a potential therapy for polyglutamine disorders (16 November, 2010)

  W M C van Roon-Mom, M M Evers, J C T van Deutekom, S A M Mulders, A M Aartsma-Rus, J T den Dunnen, G-J B van Ommen
• Experimental therapeutics: preclinical: B10 Huntingtin specific camelid VHH selected from an immunised llama phage display library (16 November, 2010)

  M H Schut, B A Pepers, R Klooster, J T den Dunnen, G-J B van Ommen, W M C van Roon-Mom
• Experimental therapeutics: preclinical: B11 Targeting the Nrf2 pathway in Huntington's disease: fumaric acid esters as a new therapeutic option in neurodegeneration? (16 November, 2010)

  G Ellrichmann, D-H Lee, C Reick, L Arning, E Petrasch-Parwez, C Saft, R Gold, R A Linker
• Experimental therapeutics: preclinical: B12 Treatment with arimoclomol does not lead to rescue of motor or striatal deficits in the YAC128 mouse model of Huntington's disease (16 November, 2010)

  M A Pouladi, J Carroll, R dar Santos, L Bertram, M R Hayden
• Experimental therapeutics: preclinical: B13 NP03, a low dose lithium microemulsion, improves motor function and rescues striatal pathology without toxicity in the YAC128 mouse model of Huntington's disease (16 November, 2010)

  M A Pouladi, E Brilluad, Y Xie, S Franciosi, W-N Zhang, M Zapala, E Compte, P Poucheret, J-C Maurel, C Néri, M R Hayden
• Experimental therapeutics: preclinical: B14 Neurotrophic factors secreting mesenchymal stem cells attenuate quinolinic acid induced striatal lesion model suggesting autologous therapy for HD (16 November, 2010)

  O Sadan, R Barzilay, E Melamed, D Offen
• Experimental therapeutics: preclinical: B15 Rat bone marrow derived mesenchymal stem cells post differentiation to neurotrophic factor secreting cells migrate towards quinolinic acid lesion (16 November, 2010)

  O Sadan, N Shemesh, Y Cohen, E Melamed, D Offen
• Experimental therapeutics: preclinical: B16 NGF improves the spatial working memory in R6/1 Huntington's disease transgenic mice through the augmentation of cholinergic function and neurogenesis (16 November, 2010)

  H Zhang, G Petit, P M Gaughwin, X Zuo, S Ranganathan, R Smith, L Roybon, P Brundin, W C Mobley, J-Y Li
• Genetics: C01 Trinucleotide repeat instability in Huntington's disease (16 November, 2010)

  B A Pepers, J T den Dunnen, G-J B van Ommen, W M C van Roon-Mom
• Genetics: C02 Analysis of the instability of the CAG trinucleotide repeat and the age of onset in a Huntington's disease population from the Basque country (16 November, 2010)

  L Valcárcel, J Kortajarena, M García, J M Fernández, E Lezcano, J Losada, J Ruiz, A Álvarez, J M Pérez, M Iriondo, A Aguirre
• Genetics: C03 Modifiers of instability and age at onset in HD: haplotype study in the Portuguese population (16 November, 2010)

  E M Ramos, T Gillis, J Mysore, K Abuelneel, J Gusella, M MacDonald, J-M Lee, I Alonso, J Sequeiros
• Genetics: C04 The effects of GRIN gene variations on age at onset of Turkish Huntington's disease patients (16 November, 2010)

  N E Tunali, A Acar-Hazer, N Erginel-Unaltuna, H A Hanagasi
• Genetics: C05 TP53 R72P polymorphism as a modifier of age at onset of Huntington's disease (16 November, 2010)

  N E Tunali, A Acar-Hazer, N Erginel-Unaltuna, H A Hanagasi
• Genetics: C06 The β-catenin repressor GSK-3β is a modifier of age at onset in Huntington's disease (16 November, 2010)

  J A Parker, C Tourette, N Offner, R Vazquez-Manrique, A Mukhopadhyay, A Darbois, S Menet, G Dolbeau, S Schwenke, P Maison, M Orth, A Brice, A Dürr, A-C Bachoud-Lévi, H A Tissenbaum, C Néri, the European Huntington's Disease Network
• Genetics: C07 Localisation of sequence variations in PGC-1α influence their modifying effect in Huntington's disease (16 November, 2010)

  S Metzger, H Van Che, C Deyle, O Riess, H P Nguyen
• Genetics: C08 Caffeine is a modifier of age at onset in Huntington's disease (16 November, 2010)

  C Duru, C Simonin, F Richard, P Hincker, M Génin, P Charles, K Youssov, S Burnouf, J-P Azulay, C Verny, C Tranchant, C Goizet, L Defebvre, B Sablonnière, M Rousseau, L Buée, P Amouyel, O Godefroy, A Dürr, A-C Bachoud-Lévi, D Blum, P Krystkowiak
• Genetics: C09 Age at onset of Huntington's disease: rater estimates versus data based extrapolation (16 November, 2010)

  M Orth, C Schwenke, REGISTRY Investigators
• Genetics: C10 Duo as a potential genetic modifier of Huntington's disease (16 November, 2010)

  Y-C Tsai, A S Soehn, S Metzger, H P Nguyen
• Genetics: C11 Copy number variation in Huntington's disease (16 November, 2010)

  A Vittori, F Giorgini, F T Outeiro, E J Hollox
• Genetic testing and counselling: D01 Updating of guidelines for the molecular genetic predictive test in Huntington's disease (1994) (16 November, 2010)

  R MacLeod, A Tibben, M Frontali
• Genetic testing and counselling: D02 Discrepancies in reporting the upper CAG repeat allele between a central EHDN and local laboratories for centres participating in the REGISTRY project (16 November, 2010)

  O W J Quarrell, C Dumoulin, O Handley, M Ramos-Arroyo, I Biunno, P Bauer, K O'Donovan, N Peppa, G B Landwehrmeyer
• Genetic testing and counselling: D03 Prenatal diagnosis after presymptomatic testing for Huntington's disease: attitudes, decision making and emotional outcome (16 November, 2010)

  C Jauffret, M Gargiulo, A Herson, D Vauthier, M Dommergues, J Feingold, D Héron, A Dürr
• Genetic testing and counselling: D04 Young people's experiences of finding out about a family history of Huntington's disease (16 November, 2010)

  K F Keenan, E van Teijlingen, L McKee, Z Miedzybrodzka, S A Simpson
• Genetic testing and counselling: D05 Childhood experiences of persons at risk for Huntington's disease (16 November, 2010)

  L van der Meer, E van Duijn, A Tibben
• Epidemiology: E01 Huntington's disease in China (16 November, 2010)

  S Huifang, Z Pei, J-M Burgunder
• Epidemiology: E02 Juvenile Huntington's disease: history and prevalence (16 November, 2010)

  N Peppa, K O'Donovan, O W J Quarrell
• Epidemiology: E03 Determinants of survival in Huntington's disease (16 November, 2010)

  C Rinaldi, E Salvatore, I Giordano, T Tucci, L Di Maio, I Castaldo, A Filla, G De Michele
• Epidemiology: E04 Causes of death in Huntington's disease (16 November, 2010)

  A-W Heemskerk, R A C Roos
• Epidemiology: E05 Prevalence of Huntington's disease in Feira Grande, a small city in Northeastern Brazil (16 November, 2010)

  M A Alencar, A M Lopez, E Figueiredo, C G Porciúncula, I Monlleó
• Clinical characteristics: F01 The European HD Network REGISTRY: Current status and future directions (16 November, 2010)

  O Handley, G B Landwehrmeyer, REGISTRY Steering Committee
• Clinical characteristics: F02 Observing Huntington's disease (HD): the European Huntington's Disease Network's REGISTRY (16 November, 2010)

  The European Huntington's Disease Network
• Clinical characteristics: F03 Huntington Quality Of Life Interview (HQOLI): a new huntington's disease-specific quality of life instrument (16 November, 2010)

  E Clay, J Dorey, J Tedroff, C Verny, M Toumi, S Abélléa
• Clinical characteristics: F04 Quality of life in Huntington's disease: a comparative study investigating the impact on spouses of those with premanifest and early disease (16 November, 2010)

  J E Read, T P A, D R Langbehn, G Owen, A Dürr, B R Leavitt, R A C Roos, J C Stout, S J Tabrizi, D Craufurd, TRACK-HD investigators
• Clinical characteristics: F05 The experience of a genetic brain disorder: cultural and social perspectives on huntington's disease (16 November, 2010)

  N Hagen, Å Petersén, S Lundin
• Clinical characteristics: F06 Late-stage huntington's disease (HD): a cohort from the European HD network (16 November, 2010)

  M Coelho, T Mestre, J J Ferreira
• Clinical characteristics: F07 Expanding the response scale of the uhdrs total functional assessment: a pilot study (16 November, 2010)

  A K Ho, R A Barker, R Swain, D O'Keefe
• Clinical characteristics: F08 The functional rating taskforce for pre-huntington's disease: results so far (16 November, 2010)

  K Evans, K Anderson, B Borowsky, J Giuliano, M Guttman, A Ho, J Paulsen, T Sills, A Vaccarino, D van Kammen, And the FuRST-pHD, PREDICT-HD investigators and coordinators
• Clinical characteristics: F09 Progression of motor symptoms prior to diagnosis in HD-gene carriers (16 November, 2010)

  T Sills, J Geraci, A Vaccarino, K Anderson, B Borowsky, J Giuliano, M Guttman, A K Ho, J Paulsen, D P van Kammen, K Evans, FuRST-pHD and PREDICT-HD investigators and coordinators
• Clinical characteristics: F10 Correlations between functional measures, voluntary and involuntary motor symptoms in HD -multivariate analysis of cross-sectional and longitudinal registry data (16 November, 2010)

  S Waters, J Tedroff, N Waters, EHDN
• Clinical characteristics: F11 Self-awareness of involuntary movements and daily living disability in huntington's disease in comparison to Parkinson's disease and cervical dystonia (16 November, 2010)

  E J Sitek, W Sołtan, D Wieczorek, M Schinwelski, P Robowski, R Reilmann, W Krysa, J Sławek
• Clinical characteristics: F12 Test-retest reliability of objective measures of posture, gait and clinical scales in huntington's disease (16 November, 2010)

  S Bohlen, C Ekwall, L Wiklund, S Rumpf, R Reilmann
• Clinical characteristics: F13 Skilled reaching impairments in a real-world reach-to-eat task in Huntington's disease (16 November, 2010)

  A Klein, L-A R Sacrey, S B Dunnett, I Q Whishaw, G Nikkhah
• Clinical characteristics: F14 Speeded tapping assesses progression of huntington's disease within one year—results from the track-HD study (16 November, 2010)

  N Bechtel, T Acharya, A Sturrock, C Jauffret, M J Say, A Patel, J E Read, E t'Hart, S J A van den Bogaard, A Dürr, B R Leavitt, R A C Roos, D R Langbehn, S J Tabrizi, R Reilmann
• Clinical characteristics: F15 Balance control in Huntington's disease: is the berg balance scale a useful test for clinical and quantitative motor assessment? (16 November, 2010)

  S Rumpf, S Bohlen, N Bechtel, R Koch, H Lange, R Reilmann
• Clinical characteristics: F16 Postural assessment in dynamic posturography—a useful motor phenotype measure for presymptomatic and manifest Huntington's disease? (16 November, 2010)

  S Rumpf, S Bohlen, N Bechtel, R Koch, H Lange, R Reilmann
• Clinical characteristics: F17 The use of an accelerometer to evaluate the performance of timed up and go test in pre-symptomatic and symptomatic huntington's disease (16 November, 2010)

  H Khalil, A Dalton, R van Deursen, A Rosser, G Ó Laighin, M Busse
• Clinical characteristics: F18 Clinical measurement of sit to stand performance in people with huntington's disease: reliability and validity for 30 seconds chair sit to stand test (16 November, 2010)

  H Khalil, R van Deursen, L Quinn, A Rosser, M Busse
• Clinical characteristics: F19 Exploring the issue of swallowing in huntington's disease (16 November, 2010)

  A K Ho, K Drake, J Cull, R A Barker, S J Tabrizi, P Lee
• Clinical characteristics: F20 Evaluating body mass composition in huntington's disease by dexa (16 November, 2010)

  E Salvatore, T Tucci, C Rinaldi, C V Russo, F Rossi, L Di Maio, A Colao, F Porcaro, A Filla, C Mainolfi, G De Michele
• Clinical characteristics: F21 Is bone density altered in early stage huntington's disease patients?—a pilot study (16 November, 2010)

  A Hughes, K Price, D Mason, B Evans, R Pettit, W Evans, A Rosser
• Clinical characteristics: F22 An assessment of alcohol abuse on cognitive abilities, executive functions and motor signs in huntington's disease (16 November, 2010)

  S Irving, M Milders, S A Simpson
• Clinical characteristics: F23 Incidence, course and predictors of apathy in Huntington's disease: a 2-year prospective study (16 November, 2010)

  N Reedeker, J A Bouwens, E van Duijn, E J Giltay, R A C Roos, R C van der Mast
• Clinical characteristics: F24 Differences in companion and subject ratings of subjects' behaviour using the frontal systems behaviour scale (FrSBe)- findings from the track-hd study (16 November, 2010)

  J Callaghan, D Craufurd, T Acharya, A Dürr, B R Leavitt, R A C Roos, D R Langbehn, J C Stout, S J Tabrizi, TRACK-HD Investigators
• Clinical characteristics: F25 Clinical criteria of Huntington's disease phenocopies and cases in Czech Republic (16 November, 2010)

  J Klempíř, J Židovská, J Roth
• Cognitive/Neuropsychology: G01 Neural correlates of empathy and context evaluation in Huntington's disease patients (16 November, 2010)

  E Lepron, H Gros, F Calvas, G Viallard, J-F Démonet
• Cognitive/Neuropsychology: G02 Attention and inhibition in Huntington's disease (16 November, 2010)

  E t‘Hart, K van de Hiele, C Jurgens, R Reijntjes, H Middelkoop, R A C Roos, G van Dijk
• Cognitive/Neuropsychology: G03 Visuomotor integration deficits in premanifest and early manifest Huntington's disease in the TRACK-HD study (16 November, 2010)

  M J Say, R Jones, R I Scahill, E M Dumas, A J Coleman, R dar Santos, D Justo, C Campbell, S Queller, S J Tabrizi, J C Stout, all the TRACK-HD Investigators
• Cognitive/Neuropsychology: G04 An exploratory analysis of the sensitivity of the Montreal Cognitive Assessment in Huntington's Disease (16 November, 2010)

  R Fullam, E Howard, J Pridham, J Callaghan, D Craufurd, J Thompson
• Cognitive/Neuropsychology: G05 Memory for object locations in preclinical Huntington's disease (16 November, 2010)

  A Frick, Å Wahlin, C Graff, G Byrne, T-B Robins Wahlin
• Cognitive/Neuropsychology: G06 Verbal learning and memory in preclinical Huntington's disease (16 November, 2010)

  T-B Robins Wahlin, A Frick, Å Wahlin, G Byrne
• Cognitive/Neuropsychology: G07 Differences between Huntington's disease and spinocerebellar ataxia types 1 and 2 on cognitive and behavioural profile (16 November, 2010)

  P Soliveri, C Mariotti, D Paridi, D Monza, C Tomasello, M Panzeri, F Taroni, A Albanese, F Girotti
• Biomarkers: H01 Significant biological and clinical change detected over 1 year in premanifest and early stage Huntington's disease in the TRACK-HD study (16 November, 2010)

  S J Tabrizi, A Dürr, R A C Roos, B R Leavitt, R Jones, G B Landwehrmeyer, H Johnson, S L Hicks, C Kennard, R Reilmann, D Craufurd, H D Rosas, C Frost, D R Langbehn, R I Scahill, J C Stout, TRACK-HD Investigators
• Biomarkers: H02 Low levels of transforming growth factor β1 in Huntington's disease peripheral macrophages and brain glial cells (16 November, 2010)

  A Silvia, S Orobello, T Martino, A M Griguoli, E Amico, F Squitieri
• Biomarkers: H03 Cerebral and extracerebral cholesterol biosynthesis is impaired in Huntington's disease patients (16 November, 2010)

  V Leoni, C Mariotti, L Nanetti, C Tomasello, E Salvatore, G De Michele, F Soletti, A Bentivoglio, M Bandettini di Poggio, G Abbruzzese, S Piacentini, F Squitieri, M Valenza, E Cattaneo, S Di Donato
• Biomarkers: H04 The relationship of hypothalamic pituitary adrenal axis dysfunction to mood and cognitive changes in the early stages of Huntington's disease (16 November, 2010)

  C Shirbin, J C Stout, A Churchyard, E Chiu, A J Hannan, T Pang, A Komiti, P Chua
• Biomarkers: H05 Gene expression profile in fibroblasts of Huntington's disease patients and controls (16 November, 2010)

  E Marchina, A Bozzato, S Ferraboli, C Agosti, L Rozzini, G Borsani, S Barlati, A Padovani
• Biomarkers: H06 Cross sectional and longitudinal 3T magnetic resonance spectroscopy in a TRACK-HD cohort of individuals with premanifest and early Huntington's disease (16 November, 2010)

  A Sturrock, C Laule, J Decolongon, R dar Santos, A J Coleman, S Creighton, N Bechtel, R Reilmann, M R Hayden, S J Tabrizi, A L Mackay, B R Leavitt
• Biomarkers: H07 Primary skin fibroblast cultures in Huntington's disease research (16 November, 2010)

  L Hasholt, S B Nielsen, N H Skotte, J E Nielsen, A Nørremølle
• Imaging: I01 Multimodal MRI assessment: a biomarker of presymptomatic Huntington's disease (16 November, 2010)

  F Squitieri, C Sanchez-Castaneda, A Cherubini, F De Gregorio, U Sabatini
• Imaging: I02 Automated longitudinal measures of global and regional brain volume change in premanifest and early Huntington's disease (16 November, 2010)

  C Gibbard, R I Scahill, I Malone, A Dürr, B R Leavitt, R A C Roos, S J Tabrizi, N Hobbs, the TRACK-HD investigators
• Imaging: I03 Magnetisation transfer MR imaging demonstrates degeneration of the subcortical and cortical grey matter in Huntington's disease (16 November, 2010)

  A Ginestroni, E Ghelli, C Mechi, S Pradella, A M Romoli, M Mascalchi, S Piacentini
• Imaging: I04 Magnetic transfer imaging in premanifest and manifest Huntington's disease: results from the TRACK-HD study (16 November, 2010)

  S J A van den Bogaard, E M Dumas, J Milles, M van Buchem, J van der Grond, R A C Roos
• Imaging: I05 Changes in iron concentrations in Huntington's disease (16 November, 2010)

  E Dumas, M Versluis, S J A van den Bogaard, A Webb, J van der Grond, R A C Roos
• Imaging: I06 Correlations between structural damage and functional deficits in early Huntington's disease (16 November, 2010)

  C Delmaire, E M Dumas, M Sharman, S J A van den Bogaard, R Valabregue, C Jauffret, R Reilmann, J C Stout, D Craufurd, S J Tabrizi, R A C Roos, S Lehéricy, A Dürr
• Imaging: I07 Image-HD: a functional magnetic resonance imaging study of spatial working memory in Huntington's disease (16 November, 2010)

  N Georgiou-Karistianis, S-P Carron, I Bohanna, J C Stout, A Churchyard, P Chua, E Frajman, G Egan
• Imaging: I08 fMRI shows an distributed extrastriatal network of altered neural activation in premanifest Huntington's disease gene carriers (16 November, 2010)

  M Novak, B Draganski, S Henley, J Warren, R Frackowiak, S J Tabrizi
• Imaging:

  I09 Brain glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG₃₃ repeat length in the Huntington's disease gene

  (16 November, 2010)

  F Squitieri, M Esmaeilzadeh, T Martino, A Ciarmiello
• Imaging: I10 In vivo evidence of decreased nigrostriatal terminals in Huntington's disease: a SPECT study (16 November, 2010)

  L Kiferle, E Unti, D Volterrani, P De Feo, C Rossi, V Nicoletti, U Bonuccelli, R Ceravolo
• Imaging: I11 Longitudinal MRI and MRSI characterisation of the quinolinic acid rat model for excitotoxicity: unique recovery of N-acetyl aspartate levels (16 November, 2010)

  O Sadan, N Shemesh, E Melamed, D Offen, Y Cohen
• Clinical care and management: J01 EHDN standards of care occupational therapy guidelines (16 November, 2010)

  C Cook, K Page, A Wagstaff, D Rae, S A Simpson
• Clinical care and management: J02 Physical therapy for patients with Huntington's disease: effects of a treatment program and intercorrelation between outcome measures (16 November, 2010)

  C Ekwall, S Bohlen, R Reilmann, L Wiklund
• Clinical care and management: J03 Falls in institutionalized patients with huntington's disease: large numbers, minor consequences (16 November, 2010)

  S Adema, T Stor
• Clinical care and management: J04 The effect of video game-based exercise on dynamic balance and mobility in individuals with Huntington's disease (16 November, 2010)

  D Kegelmeyer, N Fritz, S Kostyk, A Kloos
• Clinical care and management: J05 Multi- and interdisciplinary collaboration between the music therapist and other professionals in huntington's patient care (16 November, 2010)

  M Bruggen-Rufi, I Jansen, E van Zwol
• Clinical care and management: J06 Nutritional management of individuals with Huntington's disease: EHDN standards of care nutritional guidelines (16 November, 2010)

  A Brotherton, L Campos, A Rowell, V Zoia, S A Simpson
• Clinical care and management: J07 Guidelines for the oral health of adults with Huntington's disease (16 November, 2010)

  G Manley (Chairman), A Carlsson, B Ahlborg, Å Mårtensson, M B Nilsson, H Lane, A Balazs, A Vaalburg, D Wong, P van Splunter
• Clinical care and management: J08 The oral health and dental treatment of adults with Huntington's disease (16 November, 2010)

  H Lane, G Manley
• Clinical care and management: J09 When do voice changes affect quality of life in Huntington's disease? (16 November, 2010)

  A K Ho, J Cull, K Drake, R A Barker, S J Tabrizi, P Lee
• Clinical care and management: J10 Speech and language therapy guidelines for Huntington's disease patients (16 November, 2010)

  A-W Heemskerk, A Hamilton, D Rae, S A Simspon
• Clinical care and management: J11 A pilot study on respiratory function in people with huntington's disease (16 November, 2010)

  U Jones, S Enright, M Busse, A Rosser
• Clinical care and management: J12 Aggression among institutionalized patients with huntington's disease (16 November, 2010)

  S Adema, I Jansen, E van Zwol
• Clinical care and management: J13 Prescription usage for treatment of irritability, perseverative behaviors, and chorea in huntington's disease (16 November, 2010)

  E van Duijn, M Groves, D Craufurd, K Anderson, M Guttman, E Wexler, S Perlman, A Rosenblatt, D P van Kammen, J Giuliano, J-M Burgunder, N Goodman, L Goodman
• Clinical care and management: J14 Caregiver burden in huntington's disease (16 November, 2010)

  E Cubo, N P Mariscal, C G Muñoz
• Clinical care and management: J15 A care model in huntington's disease: delivering care with carers (16 November, 2010)

  G El-Nimr, S Tams
• Clinical care and management: J16 Coordinated multidisciplinary care for ambulatory HD-patients. Appreciation by patients, caregivers and healthcare professionals (16 November, 2010)

  R Veenhuizen
• Clinical care and management: J17 Huntington's disease—a training gap for mental health services? (16 November, 2010)

  L Johnston, T Johnston
• Clinical care and management: J18 Multidisciplinary teamwork in Sweden (16 November, 2010)

  C Hvalstedt, A Carlsson, B Ahlborg, G Fredlund, L Hartelius, U Hösterey-Ugander, Å Mårtensson, J Wahlström
• Clinical care and management: J19 Assessing Huntington's disease patients' wishes with regard to the nursing home (16 November, 2010)

  L van Gelder, E Hoffmann, M Bosma, I Jansen, E van Zwol
• Clinical care and management: J20 Euthanasia in Huntington's disease patients in the netherlands: a reconnaissance (16 November, 2010)

  S Adema, I Jansen, E van Zwol
• Clinical care and management: J21 European-huntington's disease burden study (EURO-HDB) - Preliminary results for Italy and France (16 November, 2010)

  J Dorey, J Tedroff, F Squitieri, N De Nicola, D Urbinati, M Lamure, C Verny, M Toumi
• Clinical care and management: J22 Inter-disciplinary clinic for Huntington's disease in North Staffordshire, UK (16 November, 2010)

  G El-Nimr
• Rehabilitation: K01 Intensive multidisciplinary rehabilitation for Huntington's disease in Italy: results in a cohort of patients with consecutive treatments over 5 years (16 November, 2010)

  P Zinzi, D Salmaso, P Zappata, R De Grandis, S Maceroni, L Basmagi, A Bentivoglio, M Frontali, G Jacopini
• Rehabilitation: K02 Usefulness of the Unified Huntington's Disease Rating Scales and scores in the rehabilitation of patients with Huntington's disease (16 November, 2010)

  H Lange
• Rehabilitation: K03 A multidisciplinary intensive rehabilitation programme for individuals with Huntington's disease: preliminary results from the pilot project (16 November, 2010)

  A Piira, L Øie, S F Knutsen, M van Walsem, J Frich
• Experimental therapeutics: clinical: L01 Global site and investigator database (GSID-HD): a new tool to promote research collaboration and manage efficient clinical trials in Huntington's disease (16 November, 2010)

  J Giuliano, T Kim, J Shun, D P van Kammen
• Experimental therapeutics: clinical: L02 Prescription patterns for Huntington's disease in Europe: results from the REGISTRY observational study (16 November, 2010)

  T Mestre, M Coelho, J J Ferreira, The European Huntington's Disease Network (EHDN) REGISTRY study group
• Experimental therapeutics: clinical: L03 Use and impact of neuroleptics in Huntington's disease: a prospective cohort study of the Huntington French speaking group (16 November, 2010)

  G Dolbeau, A Lombard, K Youssov, A Dürr, P Charles, C Verny, J-P Azulay, P Krystkowiak, C Simonin, C Tranchant, C Goizet, P Damier, F Supiot, E Broussolle, J-F Démonet, R-M Marie, M Verin, A-C Bachoud-Lévi, P Maison
• Experimental therapeutics: clinical: L04 Risperidone long acting injection stabilises juvenile Huntington's disease: case series (16 November, 2010)

  L Johnston, T Johnston
• Experimental therapeutics: clinical: L05 Huntexil (pridopidine) improves voluntary motor function in patients with Huntington's disease: results from the phase 3 study MermaiHD (16 November, 2010)

  F Squitieri, G B Landwehrmeyer, J Garcia de Yebenes, R Reilmann, A Rosser, A Sword, Å Rembratt, J Tedroff